Dynavax Technologies Co. (NASDAQ:DVAX - Get Free Report)'s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $13.20, but opened at $12.05. Dynavax Technologies shares last traded at $12.30, with a volume of 517,616 shares traded.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on the stock. HC Wainwright upped their target price on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a "buy" rating in a research report on Tuesday, January 14th. The Goldman Sachs Group lowered shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and cut their target price for the stock from $15.00 to $12.00 in a research report on Tuesday. Finally, StockNews.com downgraded shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Wednesday.
Read Our Latest Stock Analysis on Dynavax Technologies
Dynavax Technologies Price Performance
The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market capitalization of $1.68 billion, a P/E ratio of 98.58 and a beta of 1.32. The firm's 50 day simple moving average is $12.80 and its two-hundred day simple moving average is $11.93.
Institutional Trading of Dynavax Technologies
Several hedge funds have recently added to or reduced their stakes in DVAX. Assenagon Asset Management S.A. bought a new stake in Dynavax Technologies in the third quarter worth $8,291,000. Norges Bank bought a new position in shares of Dynavax Technologies during the fourth quarter valued at about $7,762,000. PDT Partners LLC bought a new position in shares of Dynavax Technologies during the third quarter valued at about $3,967,000. WINTON GROUP Ltd raised its stake in shares of Dynavax Technologies by 339.0% during the fourth quarter. WINTON GROUP Ltd now owns 426,814 shares of the biopharmaceutical company's stock valued at $5,450,000 after acquiring an additional 329,579 shares during the last quarter. Finally, Trexquant Investment LP raised its stake in shares of Dynavax Technologies by 48.7% during the fourth quarter. Trexquant Investment LP now owns 776,397 shares of the biopharmaceutical company's stock valued at $9,915,000 after acquiring an additional 254,405 shares during the last quarter. 96.96% of the stock is owned by institutional investors.
About Dynavax Technologies
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
See Also
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
